Mann Dean L, Celluzzi Christina M, Hankey Kim G, Harris Kristina M, Watanabe Ryuko, Hasumi Kenichiro
Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Ann N Y Acad Sci. 2009 Sep;1174:41-50. doi: 10.1111/j.1749-6632.2009.04934.x.
Dendritic cells (DCs) are potent antigen-presenting cells that have been used in cancer immunotherapy. To take advantage of the ability of DCs to acquire antigenic materials from their environment and generate primary as well as recall immune responses, 37 patients with advanced cancers were enrolled in a series of protocols based on direct intratumoral injection of immature DCs. To augment antigen uptake and antitumor immune response, DC injection was combined with radiotherapy or chemotherapy and/or injection of activated T cells. Treatments were well tolerated with no adverse reactions. Clinical responses were based on Response Evaluation Criteria in Solid Tumors, with the majority of patients showing stable disease. One of two patients who also received local radiation achieved a sustained complete response at injected and metastatic sites. The clinical responses observed in cancer patients with advanced disease suggest potential effectiveness of combination strategies and establish the basis for the current treatment protocol that is underway.
树突状细胞（DCs）是一种强大的抗原呈递细胞，已被用于癌症免疫治疗。为利用DCs从周围环境获取抗原物质并产生初次及再次免疫反应的能力，37例晚期癌症患者参加了一系列基于瘤内直接注射未成熟DCs的方案。为增强抗原摄取和抗肿瘤免疫反应，DC注射与放疗或化疗和/或活化T细胞注射相结合。治疗耐受性良好，无不良反应。临床反应基于实体瘤疗效评价标准，大多数患者病情稳定。两名同时接受局部放疗的患者中有一名在注射部位和转移部位实现了持续完全缓解。在晚期癌症患者中观察到的临床反应表明联合策略具有潜在有效性，并为正在进行的当前治疗方案奠定了基础。
